Introduction
Gastrointestinal tumors are aggressive cancers and known for their resistances to chemotherapeutic treatment approaches. Gastrointestinal tumors are very heterogeneous, and hence there is a strong clinical need to clearly define predictive biomarkers such as Epstein-Barr virus in virally-induced cancers [1] or the consensus
Moehler/Göpfert/Lenz Oncol Res Treat 2018;41:313-315 314 est part relating to the 'cancer immunity cycle', are depicted in figure 1 [10] and will be highlighted below. Discussed are novel strategies currently under development, including tumor-associated macrophages (TAM), myeloid-derived suppressor cells (MDSC), and regulatory T cells (Tregs) as new immunotherapeutic targets. Additionally, the blockade of glucocorticoid-induced TNFR-related protein (GITR), indoleamine 2 3-dioxygenase (IDO), colony-stimulating factor 1 receptor (Csf1R), and Wnt signaling pathways as combination strategies offers capable approaches for overcoming immune silencing within the nonresponsive or resistant tumor microenvironment.
In comparison to circulating Tregs, GITR is highly expressed on tumor-infiltrating Tregs. Overexpression of GITR correlates with poor prognosis in colorectal, hepatocellular, and renal cancers. Therapeutic modulation of GITR is associated with Treg depletion and stronger antitumor immunity via increased levels of cytotoxic T cells [11] .
IDO as a strategic target shows only low expression in normal healthy tissues, whereas strong upregulation is seen in different tumor entities. Overexpression of IDO in non-small cell lung cancer (NSCLC), cervical, colon, pancreatic, and liver cancers was associated with poor prognosis and a higher frequency of lymph node metastasis. As previously described for esophageal adenocarcinoma [5] , the IDO gene is upregulated in pre-and post-treatment biopsies. IDO in primary tumors leads to a lack of tryptophan and subsequent decrease in T lymphocytes [12] . In ongoing phase I/II trials, the new IDO inhibitor epacadostat is combined with nivolumab (NCT02327078) or pembrolizumab (NCT03085914) in colorectal cancer patients.
Csf1R is normally expressed by monocytes, monocytic MDSC, and macrophages. Suppression of the Csf1R signaling pathway in pancreatic cancer was associated with decreased TAM and Tregs, reduced tumor progression, and increased T-cell infiltration. An adverse effect was the upregulated expression of checkpoint molecules such as CTLA-4 on T cells and PD-L1 on tumor cells, which suggests that a combination with checkpoint inhibitors may be warranted [13, 14] . As described for colorectal and pancreatic cancer [2, 4] , Csf1R blockade induced synergistic effects when combined with other treatment strategies, such as CD40 agonism. One trial combined the Csf1R inhibitor cabiralizumab with nivolumab, with or without chemotherapy, in metastatic pancreatic cancer (NCT03336216 and NCT002526017). The combination was well tolerated. In comparison to single-agent treatment, combined nivolumab and cabiralizumab induced prolonged tumor control and increased overall survival in individual patients.
Constitutive activation of the canonical Wnt signaling pathway is an important event in gastrointestinal tumorigenesis. Upregulation of Wnt-associated proteins such as Wnt-1, -2, and -5a and loss of Wnt inhibitors such as Dickkopf-related protein 1 (DKK-1) and Axin have been shown in lung, esophageal, pancreatic, hepatocellular, bile duct, and gastric cancers [15, 16] . Serum levels of DKK-1 in gastric cancer patients seemed to correlate with TNM staging and poor prognosis [17] [18] [19] . As DKK-1 promotes an immunosuppressive tumor milieu by stimulation of MDSC, Gomceli et al. [19] proposed serum DKK-1 levels as a novel serological marker. Currently, there are 2 DKK-1-neutralizing antibodies (BHQ880 and DKN-01) which are well tolerated and clinically effective in advanced tumors such as multiple myeloma or NSCLC. Similar results are expected for the treatment of gastric cancers [20] . In a running clinical trial, patients with gastric cancer are receiving DKN-01 with paclitaxel or pembrolizumab (NCT02013154).
Virotherapy
Finally, oncolytic viruses, such as measles, herpes simplex (HSV), or parvovirus, may be additional novel treatment options Fig. 1 . Summary of therapeutic strategies in the context of the 'cancer immunity cycle'. As described in the text, combining different treatment strategies leads to additional benefit and can prevent tumor resistance mechanisms (adapted from [6, 27] ).
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Oncol Res Treat 2018;41:313-315 315 to redirect and reboost the human immune system by release of additionaly new tumor antigens [10, 21, 22] . T-VEC, a double mutated HSV-1 virus, releasing GM-CSF, was well tolerated by patients with breast, head/neck, and gastrointestinal cancers [23] . Due to the upregulated expression of checkpoint molecules, such as PD-L1, after virotherapy, combinations with checkpoint inhibitors have shown synergistic effects and may enhance response rates [24, 25] . Combination studies with pembrolizumab or Atezolizumab are currently under investigation in hepatocellular carcinoma, breast cancer and gastrointestinal liver metastases (NCT02509507 and NCT03256344). A further running clinical trial is testing the effect of T-VEC with capecitabine and chemoradiation in rectal cancer patients (NCT03300544). The modified vaccinia poxvirus Pexa-Vec (JX-594) is also currently under development with nivolumab in advanced hepatocellular carcinoma (NCT03071094), and with durvalumab ± tremelimumab in colorectal cancer (NCT03206073), and with sorafenib in hepatocellular carcinoma (NCT02562755). Further analyses and clinical trials will clarify the treatment efficacy of these oncolytic viruses in gastrointestinal cancers [26] .
Disclosure Statement
Markus Moehler acknowledges receiving the following: grants/research support: AIO, Amgen, BMS, EORTC, Merck, MSD, Taiho, Roche; honoraria or consultation fees: Amgen, AstraZeneca, BMS, Falk, Lilly, MCI, Merck, MSD, Nordic, Pfizer, Roche, Servier. Katrin Göpfert declares no conflict of interest. Heinz-Josef Lenz received advisory board fees and clinical trial support from BMS, Merck KG and Genentech/Roche.
